Company news
Palisade Bio, Inc. news in 2026
Palisade Bio, Inc.'s news releases, calls and decks from 2026, newest first.
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
October 28, 2026
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
October 20, 2026
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
October 12, 2026
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
September 28, 2026
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
September 23, 2026
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
September 22, 2026
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
September 21, 2026
Palisade Bio to Participate in Upcoming Investor Conferences
September 3, 2026
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
August 10, 2026
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
July 10, 2026
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
June 29, 2026
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
June 11, 2026
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
June 8, 2026
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
May 27, 2026
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
May 12, 2026
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
May 5, 2026
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
April 15, 2026
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
April 8, 2026
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
March 29, 2026
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
March 1, 2026
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
February 23, 2026
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
February 16, 2026
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
February 9, 2026
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 5, 2026
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
January 29, 2026
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
January 16, 2026
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
January 7, 2026